Literature DB >> 22687589

A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.

Mark V Sherrid1, Milla Arabadjian.   

Abstract

Hypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, we offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22687589     DOI： 10.1016/j.pcad.2012.04.003

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN： 0033-0620            Impact factor:   8.194


  5 in total

1.  Disopyramide as rescue treatment in a critically ill infant with obstructive hypertrophic cardiomyopathy refractory to beta blockers.

Authors:  Moises Rodriguez-Gonzalez; Ana Castellano-Martinez; Branislava Grujic; María Azahara Prieto-Heredia
Journal:  J Cardiol Cases       Date:  2017-04-14

2.  Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.

Authors:  Arnon Adler; Dana Fourey; Adaya Weissler-Snir; Waseem Hindieh; Raymond H Chan; Michael H Gollob; Harry Rakowski
Journal:  J Am Heart Assoc       Date:  2017-05-26       Impact factor: 5.501

3.  Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study.

Authors:  Raffaele Coppini; Cecilia Ferrantini; Josè Manuel Pioner; Lorenzo Santini; Zhinuo J Wang; Chiara Palandri; Marina Scardigli; Giulia Vitale; Leonardo Sacconi; Pierluigi Stefàno; Laura Flink; Katherine Riedy; Francesco Saverio Pavone; Elisabetta Cerbai; Corrado Poggesi; Alessandro Mugelli; Alfonso Bueno-Orovio; Iacopo Olivotto; Mark V Sherrid
Journal:  JACC Basic Transl Sci       Date:  2019-10-09

4.  Indications for Surgery in Obstructive Hypertrophic Cardiomyopathy.

Authors:  Mark V Sherrid
Journal:  J Am Heart Assoc       Date:  2020-12-21       Impact factor: 5.501

Review 5.  Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice.

Authors:  Mark V Sherrid
Journal:  Curr Cardiol Rev       Date:  2016
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.